Putting a Price on Exercise After Colon Cancer Treatment

George Padron
Oncology Care, GI Cancers, Managed Care, Value Based Care | Aug 4, 2026
A JCO cost-utility analysis of the CHALLENGE trial found a structured exercise program after colon cancer chemotherapy was both less costly and more effective.

AI for Managed Care Administration: Enhancement or Replacement? (Part 2)

George Padron
Podcasts, Healthcare Systems & Business, Digital Health & AI, Prior Authorization, Value Based Care | Aug 3, 2026
Dr. Randy Vogenberg discusses integrating AI into managed care, focusing on clinical pathways and expert guidelines. (Part 2)

A Bispecific Moved Earlier in Myeloma, and Brought Its Infection Risk With It

George Padron
Oncology Care, Hematologic Malignancies, Access & Affordability, Prior Authorization | Aug 2, 2026
MajesTEC-9 in NEJM found teclistamab monotherapy improved progression-free and overall survival in earlier-line myeloma, with common grade 3-4 infections.

A Blood Test's Blind Spots: Discrepancies Between P-tau217 and Clinical Alzheimer's Disease

George Padron
Precision Medicine, Biomarker & Genomic Testing, Neurology & Mental Health, Alzheimer's & Dementia | Aug 1, 2026
P-tau217 was identified as the strongest blood marker for clinical Alzheimer's disease in a study of 1,817 Caribbean Hispanic adults; however, 37% of diagnosed patients tested negative.

Barrett's Surveillance Shifts to a Risk-Based Footing

George Padron
Oncology Care, Biomarker & Genomic Testing, GI Cancers, Population Health Management | Jul 30, 2026
AGA's new Barrett's esophagus guideline replaces uniform surveillance with risk-based intervals and names high-quality endoscopy as the key to cancer prevention.

Vessel Pattern, Not Just Stenosis, Predicted Angina Relief From Stenting

George Padron
Specialty Medicine, Cardiology, Managed Care, Value Based Care | Jul 28, 2026
An ORBITA-2 analysis in JACC found focal coronary disease predicted far greater placebo-controlled angina relief from PCI than diffuse disease.